F2RL1 and neoplasm: The combination of a PAR2 inhibitor and gefitinib in PC-9-GR xenograft model exhibited larger inhibition of tumor growth and phosphorylation of ERK, confirming that the reversal effect of PAR2 inhibition as well as the underlying mechanism in vivo.